(NRC) National Research - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US6373722023
NRC: Patient Experience, Employee Engagement, Reputation Management, Governance Solutions, Marketing Analytics
National Research Corporation (NASDAQ:NRC) specializes in delivering data-driven insights to enhance patient and employee experiences within the healthcare sector. Through its subscription-based platform, the company provides actionable analytics across critical areas such as patient satisfaction, service recovery, care transitions, and employee engagement. These tools enable healthcare organizations to identify gaps, improve operational efficiency, and align with patient and staff expectations.
The companys marketing solutions include brand tracking, competitive benchmarking, and advanced segmentation tools to analyze community needs and behaviors. This allows healthcare providers to refine their branding strategies and maintain a strong market presence. Additionally, NRC offers reputation management solutions that help organizations showcase their strengths and ensure consistent, relevant messaging to influence consumer decisions.
National Research Corporation also provides governance solutions tailored for not-for-profit healthcare boards, executives, and physician leaders. These tools support informed decision-making and strategic planning. Founded in 1981 and headquartered in Lincoln, Nebraska, the company has established itself as a key player in healthcare analytics, serving organizations across the U.S. with a focus on improving experiences and operational outcomes.
3-Month Forecast: Based on
Additional Sources for NRC Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
NRC Stock Overview
| Market Cap in USD | 342m |
| Sector | Healthcare |
| Industry | Health Information Services |
| GiC Sub-Industry | Health Care Services |
| IPO / Inception | 1997-10-10 |
NRC Stock Ratings
| Growth 5y | -78.5% |
| Fundamental | 31.7% |
| Dividend | 44.0% |
| Rel. Strength Industry | -62.2 |
| Analysts | 4/5 |
| Fair Price Momentum | 11.25 USD |
| Fair Price DCF | 20.87 USD |
NRC Dividends
| Dividend Yield 12m | 2.65% |
| Yield on Cost 5y | 1.44% |
| Annual Growth 5y | 17.98% |
| Payout Consistency | 73.1% |
NRC Growth Ratios
| Growth Correlation 3m | -71.4% |
| Growth Correlation 12m | -97.3% |
| Growth Correlation 5y | -74.1% |
| CAGR 5y | -14.94% |
| CAGR/Max DD 5y | -0.20 |
| Sharpe Ratio 12m | -0.97 |
| Alpha | -72.02 |
| Beta | 0.92 |
| Volatility | 35.92% |
| Current Volume | 76.5k |
| Average Volume 20d | 78.7k |
As of March 15, 2025, the stock is trading at USD 14.83 with a total of 76,541 shares traded.
Over the past week, the price has changed by -1.85%, over one month by -16.21%, over three months by -13.15% and over the past year by -61.85%.
Neither. Based on ValueRay Fundamental Analyses, National Research is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 31.67 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of NRC as of March 2025 is 11.25. This means that NRC is currently overvalued and has a potential downside of -24.14%.
National Research has received a consensus analysts rating of 4.00. Therefor, it is recommend to buy NRC.
- Strong Buy: 0
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, NRC National Research will be worth about 12.4 in March 2026. The stock is currently trading at 14.83. This means that the stock has a potential downside of -16.39%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 12.4 | -16.4% |